This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Apr 7, 2026
•
7 min read
🧬 Neurocrine Biosciences to acquire Soleno Therapeutics for $2.9B in “surprising” acquisition - gaining rare obesity disorder drug Vykat XR, Stipple Bio emerges from stealth with $100M Series A to develop tumor-specific epitope-targeting ADCs, Amgen's subcutaneous Tepezza (teprotumumab) meets Ph3 endpoints for thyroid eye disease treatment
Apr 6, 2026
9 min read
🧬 Anthropic acquires stealth biotech Coefficient Bio for $400M to expand AI-driven drug research and development capabilities, Novo Nordisk claims indirect data show oral Wegovy outperforms Eli Lilly's Foundayo in obesity treatment comparison, Transgene licenses NEC Bio's AI neoantigen prediction platform for TG4050 - €5M ($5.77M) plus milestones
Apr 2, 2026
8 min read
🧬 Eli Lilly's Foundayo (orforglipron) wins FDA approval for obesity treatment following Ph3 success, Korsana Biosciences to go public via Cyclerion Therapeutics reverse merger with $380M funding, Syneron Bio raises $150M Series B, advancing macrocyclic peptide drug discovery platform
Apr 1, 2026
🧬 Eli Lilly to acquire Centessa Pharmaceuticals for $6.3B to enter sleep disorder market - ultimately challenging Takeda, Ambrosia Biosciences raises $100M Series B - developing oral weight-loss medications, BMS + Faro partner on multi-year AI clinical trial protocol improvement agreement
Mar 31, 2026
🧬 Blackstone closes $6.3B fund for life sciences investing and partnerships, Royalty Pharma's $500M investment to Johnson & Johnson to co-fund autoimmune antibody JNJ-4804, FDA approves Biogen's high-dose Spinraza ASO targeting SMN2 for SMA
Mar 30, 2026
🧬 Eli Lilly + Insilico Medicine expand AI drug discovery collaboration - $115M upfront + $2.75B total value, AstraZeneca's tozorakimab hits Ph3 endpoints for chronic obstructive pulmonary disease targeting IL-33 pathway, Terrestrial Bio raises $50M Series C - developing microarray patch therapeutic delivery platform
Mar 27, 2026
🧬 Pinnacle Medicines raises $89M Series B - advancing oral peptide therapeutics platform, Neion Bio emerges from stealth with egg-based biosimilar partnership to develop three monoclonal antibodies, Insilico Medicine + Tenacia Biotechnology expand AI-driven CNS collaboration with $94.75M deal value
Mar 26, 2026
🧬 Merck & Co. to acquire Terns Pharmaceuticals for $6.7B - targeting TERN-701 leukemia drug ahead of Keytruda cliff, Biogen + Alteogen partner on subcutaneous delivery tech - $20M upfront + $559M potential milestones, Denali Therapeutics' Avlayah (tividenofusp alfa-eknm) wins FDA accelerated approval for Hunter syndrome neurologic manifestations
Mar 25, 2026
🧬 UCB to build $2B biologics manufacturing facility near Atlanta headquarters, creating 330 jobs, Ocugen advances OCU410 gene therapy targeting RORA to Ph3 for geographic atrophy following positive Ph2 results, Merck & Co. + Quotient Therapeutics partner on IBD drug discovery - $20M upfront + $2.2B milestones
Mar 24, 2026
🧬 Novartis commits $480M to expand manufacturing in Beijing and R&D operations in Shanghai, Oryon Cell Therapies raises $42M Series A - Parkinson's cell therapy replacing dopaminergic neurons, Sanofi + Kali Therapeutics partner on autoimmune tri-specific antibody KT501 - $180M upfront + $1.05B milestones
Mar 23, 2026
🧬 Earendil Labs raises $787M funding - AI-powered drugmaker developing biologics for autoimmune conditions and cancer, Novartis acquires Synnovation Therapeutics' Pikavation for $2B upfront to expand PI3Kα breast cancer portfolio, Bristol Myers Squibb's Opdivo (nivolumab) wins FDA approval for treatment-naïve classical Hodgkin lymphoma
Mar 20, 2026
🧬 Novo Nordisk's Wegovy HD (semaglutide) wins FDA approval for obesity treatment under priority voucher program, Fauna Bio + Eli Lilly achieve obesity target milestone using hibernation-inspired AI platform - triggers payment, Congruence Therapeutics raises $39.5M financing to advance small molecule correctors pipeline
